↓ Skip to main content

Dove Medical Press

Serotonin reuptake inhibitors and post-gastrostomy bleeding: reevaluating the link

Overview of attention for article published in Therapeutics and Clinical Risk Management, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
14 Mendeley
Title
Serotonin reuptake inhibitors and post-gastrostomy bleeding: reevaluating the link
Published in
Therapeutics and Clinical Risk Management, August 2015
DOI 10.2147/tcrm.s87044
Pubmed ID
Authors

Harish Patel, Vinaya Gaduputi, Sailaja Sakam, Kishore Kumar, Chukwunonso Chime, Bhavna Balar

Abstract

Serotonin reuptake inhibitors (SRIs) are one of the most commonly prescribed classes of medications with a relatively safe side-effect profile. However, SRIs are being increasingly reported to be associated with bleeding complications in patients undergoing invasive procedures resulting from inhibition of serotonin reuptake by platelets and impaired platelet aggregation. The aim of our study was to determine whether there is an increased risk of post-percutaneous endoscopic gastrostomy (PEG) bleeding in patients exposed to SRIs after controlling for other mediations known to increase the risk of bleeding and major comorbidities. This was a single-center cohort study that included who underwent PEG tube placement by standard pull-guidewire technique from July 2006 to June 2014. Patients were categorized into groups based on the medications (SRIs, aspirin, non-steroidal anti-inflammatory drugs, and anticoagulants) administered during the index hospitalization. The incidence of post-PEG bleeding was noted in two distinct post-procedure periods: within 48 hours, and between 48 hours and 14 days. A total of 637 PEG tube placements were done on 570 patients during the study period. There were 107 patients (18.8%) with major bleeding within 48 hours of PEG and 79 patients (13.9%) with major bleeding between 48 hours and 14 days. There was no significant increase in the post-PEG bleeding in patients taking a combination of an SRI along with aspirin or non-steroidal anti-inflammatory drugs. Patients on subcutaneous heparin for prophylaxis against thromboembolic events were more likely to have oozing at the PEG site requiring blood transfusion. We did not notice an increase in post-PEG bleeding in patients on SRIs. However, in view of the limitation that our study is retrospective and that there are no known significant side effects of withdrawal of SRIs for a short duration, withholding SRIs could be a safe clinical option in patients undergoing PEG tube placement.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 7%
Unknown 13 93%

Demographic breakdown

Readers by professional status Count As %
Student > Postgraduate 3 21%
Researcher 2 14%
Student > Doctoral Student 2 14%
Librarian 1 7%
Other 1 7%
Other 1 7%
Unknown 4 29%
Readers by discipline Count As %
Medicine and Dentistry 6 43%
Nursing and Health Professions 1 7%
Chemistry 1 7%
Immunology and Microbiology 1 7%
Unknown 5 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2015.
All research outputs
#16,188,873
of 25,584,565 outputs
Outputs from Therapeutics and Clinical Risk Management
#729
of 1,308 outputs
Outputs of similar age
#146,684
of 276,761 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#26
of 49 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.8. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,761 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.